EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint ( EYPT ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.39% and -85.07%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025
WATERTOWN, Mass., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and ...
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shared details on Tuesday about its pivotal Phase 3 program of Duravyu ( vorolanib intravitreal insert ) for diabetic macular edema ( DME ) and began first patient dosing, anticipated in the first quarter of 2026.
EyePoint Announces Pricing of Public Offering - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten ...
EyePoint Announces Pricing of Public Offering
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten ...
EyePoint Announces Proposed Public Offering of Common Stock - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an ...
EyePoint Announces Proposed Public Offering of Common Stock
WATERTOWN, Mass., Oct. 14, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that it has commenced an ...
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
- DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 -
Nurix Therapeutics ( NRIX ) Soars 5.6%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., Sept. 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
Gene and Oral Therapies Drive Urgency and Innovation in Retinal Care, Reshaping Ophthalmology's Future, According to Spherix Global Insights
Exton, Pennsylvania, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- In a newly published edition of Special Topix™: Ophthalmology Pipeline Opportunities 2025 ( US ) , research from Spherix Global Insights with U.S. ophthalmologists, including retina specialists, sheds light on urgent, unmet needs across ...
EyePoint Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will ...
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. EYPT, a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the ...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc.
EyePoint ( EYPT ) Q2 Revenue Drops 44%
EyePoint Pharmaceuticals ( NASDAQ:EYPT ) , a biopharmaceutical company specializing in sustained-release treatments for retinal diseases, reported its second quarter 2025 results on August 6, 2025. The company's GAAP revenue of $5.3 million missed analyst expectations of $6.65 million, while the ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q2 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -26.87% and -32.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health ( GH ) Reports Q2 Loss, Beats Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of +15.38% and +9.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025
WATERTOWN, Mass., July 30, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and ...
EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
- LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community ...
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., July 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
Rhythm Pharmaceuticals ( RYTM ) Stock Jumps 36.6%: Will It Continue to Soar?
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday - AnaptysBio ( NASDAQ:ANAB ) , Abercrombie & Fitch ( NYSE:ANF )
U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday. Shares of HEICO Corporation HEI rose sharply during Wednesday's session following better-than-expected quarterly results. Heico reported quarterly earnings of $1.12 per share which beat the analyst ...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., May 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint Announces Participation at Upcoming Investor Conferences - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. EYPT, a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q1 Loss, Tops Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 0% and 345.17%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
CAMBRIDGE, Mass., May 01, 2025 ( GLOBE NEWSWIRE ) -- Foghorn® Therapeutics Inc. ( Nasdaq: FHTX ) , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., ...
EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025
WATERTOWN, Mass., April 30, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call ...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., April 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( Nasdaq: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., April 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc.
EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
WATERTOWN, Mass., March 27, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S.
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - EyePoint Pharmaceuticals ( NASDAQ:EYPT ) , Cormedix ( NASDAQ:CRMD )
U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Friday. Shares of Li Auto Inc. LI fell sharply in today's pre-market trading after the company reported fourth-quarter results. Li Auto posted quarterly adjusted EPADS of 52 cents, up from 30 cents in ...
EyePoint Pharmaceuticals ( EYPT ) Reports Q4 Loss, Lags Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -56.10% and 21.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax ( NVAX ) Reports Q4 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 32% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
EyePoint to Present Corporate Update at TD Cowen 45th Annual Health Care Conference - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
- Company presentation scheduled on Tuesday, March 4th at 9:10am ET - - EyePoint to provide enrollment update for ongoing DURAVYU™ Phase 3 pivotal program in wet AMD and additional subgroup analyses from Phase 2 VERONA clinical trial in DME -
Amicus Therapeutics ( FOLD ) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., Feb. 17, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Regenxbio ( NASDAQ:RGNX )
Goldman Sachs downgraded Regenxbio, cutting the price target due to concerns over ABBV-RGX-314's market appeal. Data for ABBV-RGX-314 in wet AMD is expected in 2026, while Phase 3 program for diabetic retinopathy with suprachoroidal delivery is planned
Foghorn Therapeutics ( FHTX ) Soars 11.4%: Is Further Upside Left in the Stock?
Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EyePoint to Present at Guggenheim SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., Jan. 16, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. EYPT, a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J.
EyePoint to Present at the 43rd Annual J.P. Morgan Healthcare Conference - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Dec. 17, 2024 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. EYPT, a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S.
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
WATERTOWN, Mass., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc. ( NASDAQ: EYPT ) , a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory ...
EyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration
- Topline data for Phase 3 pivotal program anticipated in ...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - EyePoint Pharmaceuticals ( NASDAQ:EYPT )
WATERTOWN, Mass., Nov. 18, 2024 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals, Inc.
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals ( EYPT ) : Can the Stock Really Move This High?
The mean of analysts' price targets for EyePoint Pharmaceuticals (EYPT) points to a 175.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
